perpetuity. All rights reserved. No reuse allowed without permission.

Elevated renin activity and change in sleep apnea with primary

2 aldosteronism

3

Yonekazu Kidawara, M.D., Ph.D.¹ Manabu Kadoya, M.D., Ph.D.¹ Masataka Igeta, 4 Ph.D.² Miki Kakutani-Hatayama, M.D., Ph.D.¹ Akiko Morimoto, M.D., Ph.D.¹ Akio 5 Miyoshi, M.D., Ph.D.¹ Akinori Kanzaki, M.D., Ph.D.¹ Kosuke Konishi, M.D., 6 Ph.D.¹ Takashi Daimon, Ph.D.² and Hidenori Koyama M.D., Ph.D.¹ 7 8 9 ¹Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan 10 ²Department of Biostatistics, School of Medicine, Hyogo Medical University, 11 12 Nishinomiya, Hyogo, Japan 13 14 **Short title:** Primary aldosteronism and sleep apnea 15 **Corresponding author:** 16 Manabu Kadoya, M.D., Ph.D. 17 18 Department of Diabetes, Endocrinology and Clinical Immunology, School of 19 Medicine, Hyogo Medical University 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan 20 21 Tel: +81 798 45 6473; Fax: +81 798 45 6443 22 Email: mkadoya@hyo-med.ac.jp 23 ORCID: 0009-0004-3541-5270 24 Total words (excluding abstract and references): 2301 25 26 27 28 29 30 31 32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 ABSTRACT

34	Background: The prevalence of obstructive sleep apnea (OSA) is higher in
35	patients with primary aldosteronism (PA), while elevated renin activity after
36	treatment is associated with a lower risk of cardiovascular events. However, the
37	association of PA with degree of OSA remains unclear and it is not known
38	whether elevated renin activity in PA patients is associated with change in apnea
39	condition.
40	Methods: Cross-sectional relationships between PA (n=176) and degree of OSA
41	classified by apnea-hypopnea index (AHI) with use of an apnomonitor were
42	investigated, with the results compared with those obtained with non-PA patients
43	(n=418). Additionally, the effects of elevated renin activity on change in AHI were
44	prospectively examined in 45 patients with PA.
45	Results: Patients with PA were found to be significantly associated with severe
46	OSA even after adjustment for other clinical risk factors (odds ratio 2.08, 95%
47	confidence interval 1.09-3.95, $p = 0.025$) as compared to those without PA.
48	Furthermore, the logarithm of the renin activity after treatment and change in AHI
49	before and after treatment were significantly negatively correlated, with
50	Pearson's correlation coefficient (r = -0.364 , p = 0.014).
51	
	Conclusions: Severe OSA is more commonly seen in PA patients with
52	Conclusions: Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity
52 53	Conclusions: Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity may contribute to improvement of sleep apnea in patients with PA.
52 53 54	Conclusions: Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity may contribute to improvement of sleep apnea in patients with PA.

55 Keywords: primary aldosteronism, sleep apnea, AHI, renin activity

56

57 Introduction

58	Primary aldosteronism (PA) is recognized as one of the most common causes of
59	secondary hypertension, and affected individuals have also been shown to have
60	a higher risk for cardiovascular events and mortality independent of blood
61	pressure level as compared to patients with essential hypertension (EH) ¹⁻⁴ .
62	Obstructive sleep apnea (OSA), another well-known cause of hypertension, has
63	also been found to contribute to increased risk of cardiovascular morbidity and
64	mortality ⁵⁻⁷ . In patients with PA, the prevalence of OSA has been reported to be
65	as high as 60% to 80% ⁸ . Additionally, those patients have a tendency for higher
66	OSA prevalence as compared to patients without PA who are hypertension
67	resistant ⁹ . Another report regarding risk of PA showed that individuals with
68	maintained suppression of renin activity had increased risk of cardiovascular
69	events and death ¹⁰ . Therefore, unsuppressed renin activity is now recognized
70	as a therapeutic goal for PA patients, though it remains unclear whether elevated
71	renin activity is associated with changes related to apnea. The present study
72	was performed as a cross-sectional examination of the association of PA with

73 degree of OSA and also prospectively investigated the effect of elevated renin

74 activity on sleep apnea.

75

76 Methods

77 Study design and participants

78 From October 2010 to November 2020, 1151 patients assessed for diagnosis of 79 PA and OSA were enrolled in the Hyogo Sleep Cardio-Autonomic 80 Atherosclerosis (HSCAA) study. Out of these, 781 were hypertensive patients 81 including those with PA. For the present study, those with autonomous cortisol 82 pheochromocytoma, hyperparathyroidism, secretion, primary estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m², or dialysis treatment were 83 84 excluded (n=128). Additionally, 59 with missing baseline data regarding 85 assessment of OSA were also excluded. Finally, 594 were enrolled, and divided 86 into the PA (n=176) and non-PA (n=418) groups. Of those with PA, 45 patients were simultaneously reassessment for renin activity and sleep apnea within five 87 88 years (Figure 1). HSCAA study, which has received approved by the institutional 89 ethical committee of Hyogo Medical University (approval No. 2351), was used 90 and informed written consent was obtained from each participant.

91

92 Plasma biochemical parameters

Blood samples were obtained in the morning after an overnight fast and then 93 94 quickly centrifuged to obtain plasma. Whole blood was used for hemoglobin A1c, 95 EDTA plasma for glucose and lipids, and serum for other biochemical assays. 96 Glucose measurements were performed using a glucose oxidase method and 97 an enzymatic method was used to determine serum creatinine concentration. 98 Estimated glomerular filtration rate in each patient was calculated using an 99 equation for Japanese subjects, as follows: estimated glomerular filtration rate (mL/min per 1.73 m²)=194×age (years)^{-0.287}×S-creatinine^{-1.094} (if female,×0.739). 100 Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were 101 102 measured using an enzyme immunoassay with the patient at rest in a supine 103 position for 30 minutes.

104

105 Diagnosis of primary aldosteronism

Patients were diagnosed with PA based on a PAC (pg/mL) to PRA (ng/mL/hour)

107 ratio (ARR) ≥200 at screening and at least one positive result from confirmatory

108 tests for PA diagnosis (saline infusion test, captopril challenge test,

109 furosemide-upright test) at the time of admission, according to previously

- 110 reported guidelines ^{11,12}.
- 111

112 Assessment of sleep apnea

113 To determine the presence of sleep apnea, an apnomonitor device (SAS-2100, 114 Nihon Kohden, Tokyo, Japan; supplied by Teijin, Tokyo, Japan) was used to 115 provide apnea-hypopnea index (AHI) values. Criteria presented in The American 116 Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated 117 Events, version 2.1, were used for analysis of respiratory events, as follows. 118 Apnea was defined when the amplitude ratio to normal breathing was ≤10% with 119 air flow lasting ≥ 10 seconds, and hypophea when the amplitude ratio to normal 120 breathing was \leq 70% with air flow lasting \geq 10 seconds and associated with a 4% 121 decrease in oxygen saturation. AHI was calculated as the average number of 122 apnea and hypopnea episodes per hour. When the decrease was 3% or more 123 per second or the sensor was disconnected, the result was considered an 124 artifact and excluded from analysis. The degree of sleep apnea was classified 125 based on AHI values as none (0 to <5), mild (5 to <15), moderate (15 to <30), or severe (≥30) ¹³. 126

127

128 Statistical analyses

For comparisons of mean and median values of continuous variables for the 129 130 baseline clinical characteristics between PA status (PA and non-PA), and also 131 suppressed renin activity status in patients with PA (remained suppressed and 132 unsuppressed), Welch's t-test or the Mann-Whitney U-test was used. Fisher's 133 exact test was used for categorical variables. Multivariable logistic regression 134 analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) 135 values for the associations of degree of OSA with PA as compared to the non-PA 136 group adjusting for clinical factors, including potential causal factors for sleep 137 apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and renal function. In 138 addition, a Pearson's correlation coefficient was calculated to evaluate the 139 association between the change of AHI and elevation of the renin activity in PA 140 patients. The logarithmic transformation was performed to the renin activity for a 141 normal approximation. All statistical analyses were performed with EZR, version 142 1.61 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and 143 SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P 144 values are two-sided and considered to be statistically significant at <0.05

145 without adjustment for multiplicity.

146

147 **Results**

148 Baseline clinical characteristics

149 The baseline characteristics of the present patients after dividing into the PA and 150 non-PA groups are shown in **Table 1**. The distribution of degree of sleep apnea 151 in those with PA was as follows: normal (AHI <5), 26.7%; mild (AHI 5 to <15), 152 38.6%; moderate (AHI 15 to <30), 18.8%; and severe (AHI ≥30), 15.9%. Patients 153 with PA exhibited higher levels of systolic BP, diastolic BP, and plasma 154 aldosterone concentration, lower levels of fasting plasma glucose, HbA1c, and 155 plasma renin activity, and lower prevalence of diabetes and dyslipidemia, as 156 compared to the non-PA group.

157

158 The baseline clinical characteristics of the patients classified by degree of OSA 159 are presented in Table 2. Comparisons were also made between patients 160 classified according to degree of OSA and those without OSA. There were no 161 clinically significant differences in regard to smoking, diastolic BP, LDL-cholesterol, PRA, PAC, or use of anti-hypertensive drugs such as 162

163 calcium-channel blocker and diuretic agent between patients with OSA 164 regardless of severity as compared to those without OSA. Patients with OSA showed higher levels of BMI, systolic BP, FPG, and HbA1c, and a higher 165 166 prevalence for male gender and diabetes, and lower level of eGFR as compared to patients without OSA. Those with mild or moderate OSA were older than 167 168 those without OSA. As compared to patients without OSA, those with moderate 169 or severe OSA had lower levels of HDL, higher levels of TG, and a higher 170 prevalence of dyslipidemia. Users of α blocker anti-hypertensive drugs were 171 more frequently noted among patients with severe OSA as compared to those 172 without OSA. Furthermore, the prevalence of PA tended to be higher in patients 173 with severe OSA, though the difference was not significant as compared to 174 patients classified with other levels of OSA.

175

176 Relationship of PA with degree of OSA

Results of multivariable logistic analysis performed to examine the associations
of PA with each level of OSA as compared to non-PA patients are shown in **Table 3.** This analysis was fully adjusted for clinical factors, including potential causal
factors for sleep apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and

181	renal function. PA was shown to have a significant association with only severe
182	OSA. These results suggest that patients with PA are more likely than
183	hypertensive patients without PA to be complicated by severe sleep apnea under
184	adjustment of the potential causal factors for sleep apnea.
185	
186	Effects of elevated renin activity on change of sleep apnea
187	Renin activity and AHI were reevaluated after a mean of 2.5 \pm 1.6 years in 45 PA
188	patients. Pearson's correlation coefficient were used to evaluate the association
189	between the logarithm of the renin activity at reevaluation and amount of change
190	in AHI, as shown in Figure 2. This relationship was significantly negatively
191	correlated (r = -0.364 , p = 0.014).
192	
193	Discussion
194	This is the first study to assess cross-sectional associations among PA patients
195	with various degrees of OSA. Moreover, the effects of remaining suppressed
196	renin activity on sleep apnea in patients with PA were prospectively examined.
197	PA was found to be strongly associated with severe sleep apnea under
198	adjustment of the potential causal factors for sleep apnea. Additionally, they

show that elevated renin activity can potentially prevent the progression of sleepapnea in patients with PA.

201

202 Epidemiological studies have found that PA is a disease that can cause sleep apnea. Among patients with resistant hypertension, the degree of OSA has been 203 204 reported to be higher in those with hyperaldosteronism ¹⁴. The present results 205 show an association of PA with severe sleep apnea under adjustment of the potential causal factors for sleep apnea. Previously, it was suggested that 206 207 excessive aldosterone secretion causes inappropriate sodium and fluid retention 208 ⁶. Furthermore, mechanisms related to fluid movement from the lower 209 extremities to the neck caused by edema of the upper airway may contribute to the etiology of OSA ¹⁵. Another study noted that patients with OSA who 210 211 underwent diuretic treatment showed significantly improved upper airway caliber 212 and OSA, further implicating pharyngeal edema as a cause of upper airway collapse during sleep ¹⁶. Moreover, a volumetric analysis technique used with 213 214 magnetic resonance imaging demonstrated that volume of the tongue and lateral walls were independent factors related to increased risk of OSA ¹⁷. Impairment of 215 ventilatory-control mechanisms can also contribute to modulation of pharyngeal 216

217 collapsibility during sleep, thus suggesting a role for central nervous system input, which may be influenced by humoral factors ¹⁸⁻²⁰. Furthermore, basic 218 219 research results have indicated that aldosterone has a central role in increased brain renin-angiotensin activity, oxidative stress, and sympathetic drive ²¹. 220 221 Therefore, in addition to pharyngeal edema caused by inappropriate sodium and 222 fluid retention related to hyperaldosteronism, disruptions in normal central 223 respiratory mechanisms by aldosterone-induced activation of central receptors may potentially contribute to the association between PA and sleep apnea 224 225 severity.

226

Aldosterone receptor antagonists are used as therapeutic agents in patients with 227 PA. Such medication has also been indicated as effective for not only improving 228 229 hypertension but also preventing complications, including cardiovascular events. 230 Spironolactone treatment for patients with resistant hypertension has been reported to significantly decrease AHI level ²². As for pharmacological treatment 231 232 for PA, elevated renin activity has been shown useful to prevent development of 233 cardiovascular events, cardiovascular death, and renal dysfunction, thus elevated renin activity is considered to be a therapeutic goal. A possible 234

235	mechanism underlying the association between elevated renin activity and sleep
236	apnea following therapeutic intervention may be inhibition of mineralocorticoid
237	receptor activation by aldosterone antagonists or an adrenalectomy for
238	aldosterone-producing adenoma treatment ²³ . Elevated renin activity is used as
239	an indicator of suppressed mineralocorticoid receptor activation. Results of the
240	present study indicate that elevated renin activity leads to prevent progress of
241	sleep apnea.
242	
243	This study has several limitations. First, the findings may not be generalizable to
244	all patients with different blood pressure status. Second, the present cohort did
245	not take into account the effect of change in body weight, as that was not
246	possible to track. Nevertheless, the present findings are considered to provide
247	important initial information for clarification of the association of PA with sleep
248	apnea. Moreover, there was a significant negative correlation between the renin
249	activity after treatment and change in AHI before and after treatment. The results
250	suggest that the increase in renin activity reflects suppression of aldosterone
251	action, which may lead to improvement of sleep apnea via improvement of
252	pharyngeal edema.

253

254 Conclusion

- As compared to hypertensive patients without PA, patients with PA are more
- 256 likely to have severe sleep apnea. Furthermore, elevated renin activity may
- contribute to improvement of sleep apnea in patients with PA.

258

259 **Perspectives**

260 PA appears to play a fundamental role in development of sleep apnea. The 261 elevated renin activity is used as an indicator of the effects of PA treatment goals 262 as well as need for prevention of various complications. The present study 263 investigated the association of PA with degree of OSA as compared to non-PA 264 patients with hypertension and is the first to report a relationship between 265 elevated renin activity and changes in sleep apnea in PA patients. The results 266 provide important initial insight regarding the association of PA with degree of sleep apnea as well as for determining whether elevated renin activity has 267 268 effects on sleep apnea in patients with PA.

269

270 Acknowledgements

271	The authors are grateful for the excellent technical assistance provided by
272	Tomoe Ushitani and Ai Matsumoto. We also wish to thank the other investigators
273	and staff members, as well as the participants of the HSCAA study for their
274	valuable contributions.
275	
276	Funding
277	JSPS KAKENHI grants (24K19043 to Y. Kidawara, 20K18944 to A. Mrimoto) and
278	Hyogo Medical University (Hyogo Innovative Challenge to H. Koyama) were
279	received.
280	
281	Disclosures
282	There no conflicts of interest or commercial affiliations to disclose.
283	
284	Data Availability
285	The datasets generated during and/or analyzed for the current study are not
286	publicly available, though can be provided by the corresponding author upon
287	reasonable request.

288

289 Novelty and Relevance

290 What is new?

- 291 This study sheds light on the currently incompletely understood association
- 292 between PA and degree of OSA in hypertensive patients and effect of elevated
- renin activity for change in sleep apnea in patients with PA. An increased risk of
- severe OSA is revealed in patients with PA. Furthermore, it indicated that
- 295 elevated renin activity following treatment can possible to prevent sleep apnea
- 296 progression.

297 What Is Relevant?

- 298 Our results provide important initial findings to unveil the pathophysiological
- 299 factors for PA and OSA.
- 300 Clinical/Pathophysiological Implications?
- 301 PA is an important risk factor for severe OSA in hypertensive patients, and
- 302 elevated renin activity following treatment is negatively correlated with
- 303 progression of sleep apnea. These knowledge could improve the prediction and
- 304 progression of sleep apnea in patients with PA.

305

306 **References**

- 1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence
- 308 for an increased rate of cardiovascular events in patients with primary
- 309 aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. doi:
- 310 10.1016/j.jacc.2005.01.015

311	2.	Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular
312		complications in patients with aldosterone producing adenoma in Japan:
313		comparative study with essential hypertension. The Research Committee
314		of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest.
315		1995;18:370-373. doi: 10.1007/BF03347840
316	3.	Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi
317		LA. Cardiovascular outcomes in patients with primary aldosteronism after
318		treatment. Arch Intern Med. 2008;168:80-85. doi:
319		10.1001/archinternmed.2007.33
320	4.	Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications
321		associated with primary aldosteronism: a controlled cross-sectional study.
322		<i>Hypertension.</i> 2013;62:331-336. doi:
323		10.1161/HYPERTENSIONAHA.113.01060
324	5.	Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as
325		a risk factor for coronary events or cardiovascular death. Sleep Breath.
326		2010;14:131-136. doi: 10.1007/s11325-009-0298-7
327	6.	Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A,
328		Daniels S, Floras JS, Hunt CE, Olson LJ, et al. Sleep apnea and

329		cardiovascular disease: an American Heart Association/american College
330		Of Cardiology Foundation Scientific Statement from the American Heart
331		Association Council for High Blood Pressure Research Professional
332		Education Committee, Council on Clinical Cardiology, Stroke Council, and
333		Council On Cardiovascular Nursing. In collaboration with the National
334		Heart, Lung, and Blood Institute National Center on Sleep Disorders
335		Research (National Institutes of Health). Circulation. 2008;118:1080-1111.
336		doi: 10.1161/CIRCULATIONAHA.107.189375
337	7.	Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive sleep apnea
338		and risk of cardiovascular disease and all-cause mortality: a
339		meta-analysis of prospective cohort studies. Int J Cardiol.
340		2013;169:207-214. doi: 10.1016/j.ijcard.2013.08.088
341	8.	Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P,
342		Klisiewicz A, Michałowska I, Warchoł E, Januszewicz M, Kała M, et al.
343		Clinical characteristics of patients with resistant hypertension: the
344		RESIST-POL study. J Hum Hypertens. 2013;27:678-685. doi:
345		10.1038/jhh.2013.32

346 9. Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska

347		H, Bieleń P, Szwench-Pietrasz E, Warchoł-Celińska E,
348		Kołodziejczyk-Kruk S, Janas J, et al. Relationship between primary
349		aldosteronism and obstructive sleep apnoea, metabolic abnormalities and
350		cardiac structure in patients with resistant hypertension. Endokrynol Pol.
351		2013;64:363-367. doi: 10.5603/EP.2013.0019
352	10.	Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A.
353		Cardiometabolic outcomes and mortality in medically treated primary
354		aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol.
355		2018;6:51-59. doi: 10.1016/S2213-8587(17)30367-4
356	11.	Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa
357		S, Ichijo T, Otsuki M, Omura M, et al. Japan Endocrine Society clinical
358		practice guideline for the diagnosis and management of primary
359		aldosteronism 2021. Endocr J. 2022;69:327-359. doi:
360		10.1507/endocrj.EJ21-0508
361	12.	Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T,
362		Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of
363		Hypertension Guidelines for the Management of Hypertension (JSH
364		2019). <i>Hypertens Res.</i> 2019;42:1235-1481. doi:

365 10.1038/s41440-019-0284-9

366	13.	Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K,
367		Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult
368		Obstructive Sleep Apnea: An American Academy of Sleep Medicine
369		Clinical Practice Guideline. J Clin Sleep Med. 2017;13:479-504. doi:
370		10.5664/jcsm.6506
371	14.	Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding
372		SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep
373		apnea is related to aldosterone status in subjects with resistant
374		hypertension. J Clin Sleep Med. 2010;6:363-368.
375	15.	Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M,
376		Floras JS, Chan C, Bradley TD. Alterations in upper airway
377		cross-sectional area in response to lower body positive pressure in
378		healthy subjects. <i>Thorax.</i> 2007;62:868-872. doi:
379		10.1136/thx.2006.071183
380	16.	Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin
381		A. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest.
382		2007;132:440-446. doi: 10.1378/chest.07-0311

383	17.	Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens
384		R, Maislin G, Pack AI. Identification of upper airway anatomic risk factors
385		for obstructive sleep apnea with volumetric magnetic resonance imaging.
386		Am J Respir Crit Care Med. 2003;168:522-530. doi:
387		10.1164/rccm.200208-866OC
388	18.	Wolk R, Johnson BD, Somers VK. Leptin and the ventilatory response to
389		exercise in heart failure. J Am Coll Cardiol. 2003;42:1644-1649. doi:
390		10.1016/j.jacc.2003.06.007
391	19.	Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and
392		hypocapnia on sympathetic nerve responses to hypoxia in normal
393		humans. J Appl Physiol (1985). 1989;67:2095-2100. doi:
394		10.1152/jappl.1989.67.5.2095
395	20.	Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of
396		hypoxia and hypercapnia on ventilation and sympathetic activity in
397		humans. J Appl Physiol (1985). 1989;67:2101-2106. doi:
398		10.1152/jappl.1989.67.5.2101
399	21.	Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally
400		to increase brain renin-angiotensin system activity and oxidative stress in

401	normal rats.	Am J Ph	vsiol Heart	Circ Physi	iol. 2008;	294:H1067	·1074.	doi:
-----	--------------	---------	-------------	------------	------------	-----------	--------	------

- 402 10.1152/ajpheart.01131.2007
- 403 22. Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, Liang E, Bian J, Wu H,
- 404 Hui R. Effect of spironolactone on patients with resistant hypertension
- 405 and obstructive sleep apnea. *Clin Exp Hypertens*. 2016;38:464-468. doi:
- 406 10.3109/10641963.2015.1131290
- 407 23. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in
- 408 Obstructive Sleep Apnea and Metabolic Syndrome. *Curr Hypertens Rep.*
- 409 2018;20:23. doi: 10.1007/s11906-018-0819-5
- 410
- 411
- 412 Figure legends
- 413 **Figure 1. Flow of subject selection.**
- 414 eGFR, estimated glomerular filtration rate; PA, primary aldosteronis.
- 415

416 Figure 2. Association between renin activity following treatment and

- 417 amount of changes in AHI.
- 418 Correlation coefficient and p values for association between renin activity
- 419 following treatment and amount of change in AHI were calculated using a

420 Pearson's correlation coefficient.

421

Variables	PA	Non-PA	Р
Number of patients	176	418	
Age, years	57.1 ± 12.8	63.7 ± 12.2	<0.001
Male, n (%)	84 (47.7)	231 (55.3)	0.112
Body mass index, kg/m ²	25.4 ± 4.9	25.3 ± 5.2	0.682
Current smoker, n (%)	41 (23.3)	113 (27.0)	0.397
Systolic BP, mmHg	137.2 ± 15.7	131.2 ± 14.4	<0.001
Diastolic BP, mmHg	82.4 ± 10.3	76.4 ± 9.0	<0.001
LDL cholesterol, mg/dL	112.6 ± 29.4	111.8 ± 32.5	0.818
HDL cholesterol, mg/dL	54.8 ± 15.9	53.1 ± 17.0	0.273
Triacylglycerol, mg/dL	120.5 (84.0 – 165.3)	115.0 (85.0 – 171.0)	0.911
eGFR, mL/min/1.73 m ²	80.0 ± 19.2	77.6 ± 23.0	0.224
Fasting plasma glucose, mg/dL	98 (91 - 106)	101 (93 - 121)	<0.001
HbA1c (%)	5.5 (5.2 - 5.9)	5.9 (5.3 - 6.8)	<0.001
Plasma renin activity, ng/mL/hour	0.4 (0.2 - 0.6)	0.9 (0.5 - 2.1)	<0.001
Plasma aldosterone concentration, pg/mL	212.5 (153.0 – 293.8)	102.0 (63.6 – 150.0)	<0.001
Comorbidities			
Diabetes, n (%)	29 (16.5)	197 (47.1)	<0.001
Dyslipidemia, n (%)	99 (56.3)	284 (67.9)	0.009
Anti-hypertensive drugs			
Calcium channel blocker, n (%)	108 (71.5)	262 (68.8)	0.604
α blocker, n (%)	12 (7.9)	31 (8.1)	1.000

Table 1. Comparisons of baseline clinical characteristics

Diuretic agent, n (%)	18 (11.9)	34 (8.9)	0.375	
Sleep apnea				
AHI, n (%)	10.0 (4.8-20.3)	9.7 (3.9-19.6)	0.281	
Normal (<5), n (%)	47 (26.7)	125 (29.9)	0.493	
Mild (5 to <15), n (%)	68 (38.6)	145 (34.7)	0.411	
Moderate (15 to <30), n (%)	33 (18.8)	104 (24.9)	0.130	
Severe (AHI ≥30), n (%)	28 (15.9)	44 (10.5)	0.090	

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables or number (%)

for categorical dichotomous variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as the mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate; AHI, apnea-hypopnea index

Variables	Normal (AHI <5)	Mild (AHI 5 to <15)	Moderate (AHI 15 to <30)	Severe (AHI ≥30)	P value	P value	P value
					(Normal vs.	(Normal vs.	(Normal vs.
					Mild)	Moderate)	Severe)
Number	170	214	138	72	-	-	-
Age, years	59.3 ± 14.0	62.2 ± 11.7	64.9 ± 11.4	60.6 ± 13.8	0.026	<0.001	0.489
Male, n (%)	74 (43.5)	117 (54.7)	81 (58.7)	43 (59.7)	0.039	0.011	0.031
Body mass index, kg/m ²	22.9 ± 3.6	25.1 ± 4.7	26.1 ± 4.8	30.1 ± 6.4	<0.001	<0.001	<0.001
Current smoker, n (%)	37 (21.8)	59 (27.6)	34 (24.6)	24 (33.3)	0.235	0.646	0.083
Systolic BP, mmHg	130.2 ± 14.5	133.6 ± 15.3	133.6 ± 15.3	136.4 ± 14.3	0.024	0.045	0.002
Diastolic BP, mmHg	77.6 ± 10.1	78.9 ± 9.6	77.6 ± 9.5	78.7 ± 10.2	0.221	0.990	0.458
LDL cholesterol, mg/dL	112.8 ± 33.4	110.0 ± 31.5	113.2 ± 28.8	114.2 ± 32.5	0.540	0.930	0.798
HDL cholesterol, mg/dL	55.5 ± 18.0	54.9 ± 16.0	51.0 ± 15.1	50.3 ± 17.3	0.709	0.021	0.039
Triacylglycerol, mg/dL	102 (78 - 147)	115 (84 - 154)	125 (96 - 179)	141 (106 - 194)	0.203	0.002	<0.001
eGFR, mL/min/1.73m ²	83.0 ± 21.9	78.5 ± 21.8	75.6 ± 20.4	72.1 ± 23.6	0.043	0.002	<0.001
Fasting plasma glucose, mg/dL	97 (90 - 105)	101 (93 - 116)	104 (94 - 126)	103 (95 - 118)	0.001	<0.001	<0.001
HbA1c (%)	5.4 (5.1 - 6.0)	5.7 (5.3 - 6.6)	5.9 (5.4 - 6.8)	6.0 (5.6 - 6.8)	<0.001	<0.001	<0.001
Plasma renin activity, ng/mL/hr	0.7 (0.4 - 1.6)	0.6 (0.3 - 1.2)	0.8 (0.4 - 2.1)	0.8 (0.4 -1.7)	0.234	0.222	0.595
Plasma aldosterone concentration, pg/mL	127 (74 - 198)	121 (78 - 187)	125 (80 - 195)	147 (74 - 215)	0.812	0.662	0.718
Comorbidities							
Diabetes, n (%)	47 (27.6)	84 (39.3)	62 (44.9)	33 (45.8)	0.023	0.002	0.009

Table 2. Comparisons of baseline clinical characteristics among subjects divided based on degree of sleep apnea

Dyslipidemia, n (%)	97 (57.1)	134 (62.6)	96 (70.0)	56 (77.8)	0.317	0.033	0.004
Anti-hypertensive drugs							
Calcium-channel blocker, n (%)	104 (68.9)	129 (67.2)	85 (69.1)	52 (78.8)	0.829	1.000	0.183
α blocker, n (%)	10 (6.6)	14 (7.3)	8 (6.5)	11 (16.7)	0.978	1.000	0.040
Diuretic agent, n (%)	8 (5.3)	23 (12.0)	14 (11.4)	7 (10.6)	0.051	0.105	0.260
Sleep apnea							
AHI	2.4 (1.1 - 3.6)	9.0 (7.1 - 11.5)	20.1 (16.7 - 24.2)	39.9 (33.0 - 45.6)	<0.001	<0.001	<0.001
PA, n (%)	45 (26.5)	69 (32.2)	34 (24.6)	28 (38.9)	0.264	0.814	0.077

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables, or number (%) for categorical variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; EH, essential hypertension; AHI, apnea-hypopnea Index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate

	Mild (AHI 5 to <15)		Moderate (AHI 15 to <30)		Severe (AHI ≥30)	
Variables	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р
Age, years (per 5)	1.02 (0.95 - 1.11)	0.560	1.18 (1.07 - 1.30)	0.001	1.13 (1.00 - 1.05)	0.084
Male	1.16 (0.82 - 1.63)	0.410	1.29 (0.87 - 1.91)	0.212	1.56 (0.88 - 2.78)	0.130
Body mass index, kg/m ² (per 5)	0.94 (0.78 - 1.13)	0.492	1.35 (1.1 - 1.65)	0.004	2.78 (2.08 – 3.73)	<0.001
Systolic BP, mmHg (per 10)	1.03 (0.92 - 1.16)	0.615	1.04 (0.91 - 1.19)	0.566	1.11 (0.92 – 1.34)	0.275
HbA1c (%)	1.05 (0.92 - 1.20)	0.485	1.08 (0.93 - 1.25)	0.335	1.16 (0.94 - 1.43)	0.174
eGFR, mL/min/1.73 m ² (per 5)	1.00 (0.97 - 1.05)	0.708	1.00 (0.95 - 1.05)	0.897	0.93 (0.86 – 1.00)	0.045
PA (vs. non-PA)	1.28 (0.86 - 1.90)	0.229	0.97 (0.60 - 1.57)	0.905	2.08 (1.09 – 3.95)	0.025

 Table 3. Multivariable logistic regression analysis of factors associated with degree of sleep apnea

PA, primary aldosteronism; BP, blood pressure; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval



